DMAC vs EG · $157.4M cap vs P/E 17, rev $17.28B
DiaMedica Therapeutics Inc (DMAC) versus Everest Group Ltd (EG) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Everest Group Ltd (EG) is a insurance - reinsurance company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported EG revenue for 2024-12-31 was $17.28B. Net income was $1.37B. Revenue was up 18.5% from 2023-12-31 to 2024-12-31. EG currently screens at market cap $14.52B and trailing P/E 17.2.
DMAC currently screens at market cap $157.4M. EG currently screens at market cap $14.52B and trailing P/E 17.2.
Not investment advice. Open the DMAC and EG stock pages for the full models.
Not investment advice.